OncoMatch/Clinical Trials/NCT05806580
Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma
Is NCT05806580 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies Relma-cel for relapsed or refractory b-cell lymphoma.
Treatment: Relma-cel — To observe the efficacy and safety of a second infusion of relma-cel injection in patients with relapsed or refractory B-cell lymphoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 positive
Prior therapy
Must have received: CAR-T cell therapy (Relma-cel) — initial treatment
have completed initial treatment with Relma-cel
Must have received: disease assessment — post-initial Relma-cel treatment
must have undergone at least one disease assessment post-initial Relma-cel treatment
Must have received: lymphodepleting chemotherapy (fludarabine, cyclophosphamide)
Toxicity related to lymphodepleting chemotherapy (fludarabine and cyclophosphamide), except for hair loss, must have resolved to ≤ Grade 1 or returned to baseline levels before retreatment.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05806580 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received CAR-T cell therapy and disease assessment.
Does this trial require CD19?
Yes, CD19 positive is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages